A practical reference on lyophilised powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-28. Anything still debated is marked as such rather than presented as settled.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
==== Mental health ==== Layard and others show that the most important influence on happiness is mental health. L.M. Keyes and Shane Lopez illustrate the four typologies of mental health functioning: flourishing, struggling, floundering and languishing. However, complete mental health is a combination of high emotional well-being, high psychological well-being, and high social well-being, along with low mental illness. Although health is part of well-being, some people are able to maintain satisfactory wellbeing despite the presence of psychological symptoms.
== Green sample preparation == SPME is recognized as a green analytical method for sample preparation, particularly in forensic drug analysis. This technique offers several advantages over traditional methods like liquid–liquid extraction (LLE) and solid-phase extraction (SPE), including automation, rapid sample processing, and reduced solvent usage. SPME allows for the extraction of analytes directly from complex matrices, such as biological and environmental samples, while minimizing the environmental impact associated with conventional extraction techniques.
=== Medicine === Medical technicians may sequence genes (or, theoretically, full genomes) from patients to determine if there is risk of genetic diseases. This is a form of genetic testing, though not all genetic tests involve complete genome DNA sequencing. As of 2013 DNA sequencing was increasingly used to diagnose and treat rare diseases. As more and more genes are identified that cause rare genetic diseases, molecular diagnoses for patients become more mainstream. DNA sequencing allows clinicians to identify genetic diseases, improve disease management, provide reproductive counseling, and more effective therapies. Gene sequencing panels are used to identify multiple potential genetic causes of a suspected disorder. Also, DNA sequencing may be useful for determining a specific bacteria, to allow for more precise antibiotics treatments, hereby reducing the risk of creating antimicrobial resistance in bacteria populations.
== LCRs and the protopeptides of the early genetic code == The amino acids with the highest frequency in LCRs are glycine and alanine, with their respective codons GGC and GCC being the most frequent, as well as complementary. In eukaryotes and more specifically in chordates (such as human, mouse, chicken, zebrafish and sea squirt), alanine- and glycine-rich LCRs are over-represented in recently formed LCRs and probably are better tolerated by the cell. Intriguingly, it has also been suggested that they represent the very first two amino acids and codons of the early genetic code. Thus, these two codons and their respective amino acids must have been constituents of the earliest oligopeptides, with a length of 10–55 amino acids and very low complexity. Based on several different criteria and sources of data, Higgs and Pudritz suggest G, A, D, E, V, S, P, I, L, T as the early amino acids of the genetic code. Trifonov's work largely agrees with this categorization and proposes that the early amino acids in chronological order are G, A, D, V, S, P, E, L, T, R. An evolutionary analysis observed that many of the amino acids of the suggested very early genetic code (with the exception of the hydrophobic ones) are significantly enriched in bacterial LCRs. Most of the later additions to the genetic code are significantly under-represented in bacterial LCRs. They thus hypothesize and propose that, in a cell-free environment, the early genetic code may have also produced low complexity oligo-peptides from valine and leucine.
In January 1985, the sixth generation Familia/323 was fully renewed. It was available as a hatchback (with three or five doors) or four-door saloon only for the first year; wagon and cabriolet models were added in November 1985 and March 1986 respectively. The wagon was commonly sold as a light van in Japan, but for the first time it was also available as a passenger-oriented wagon model in the Japanese domestic market. In November 1986, cumulative production of Familias (excluding vans and pickups) reached five million units; at the time, Mazda was building about 40,000 Familia/323s per month. In January 1987 a personal coupé version with its own bodywork, the Étude, was added. In February 1987 the Familia range underwent a light facelift that included replacing the old E engines with the more modern B series. In some markets, such as Indonesia, the E engine continued to be installed after the facelift. This generation of the Familia/323 was also available in a version with a turbocharged DOHC engine, with either front- or four-wheel drive, producing 140 PS (103 kW). The 4WD version (sold in either a lightweight GT or fully optioned GT-X grade) introduced in October 1985, saw some success in rally's Group A category. A limited production Japanese-only homologation special, the 4WD GT-Ae, appeared May 1988 and offered an additional ten horsepower and viscous rear limited slip differential (similar to the later BG Familia). Full time four-wheel drive was also available in more pedestrian versions like the 1.5 hatchback.
Sources: en.wikipedia.org
=== Cryopulverization === Samples with a tough extracellular matrix, such as animal connective tissue, some tumor biopsy samples, venous tissue, cartilage, seeds, etc., are reduced to a fine powder by impact pulverization at liquid nitrogen temperatures. This technique, known as cryopulverization, is based on the fact that biological samples containing a significant fraction of water become brittle at extremely cold temperatures. This technique was first described by Smucker and Pfister in 1975, who referred to the technique as cryo-impacting. The authors demonstrated cells are effectively broken by this method, confirming by phase and electron microscopy that breakage planes cross cell walls and cytoplasmic membranes. The technique can be done by using a mortar and pestle cooled to liquid nitrogen temperatures, but use of this classic apparatus is laborious and sample loss is often a concern. Specialised stainless steel pulverizers generically known as Tissue Pulverizers are also available for this purpose. They require less manual effort, give good sample recovery and are easy to clean between samples. Advantages of this technique are higher yields of proteins and nucleic acids from small, hard tissue samples - especially when used as a preliminary step to mechanical or chemical/solvent cell disruption methods mentioned above.
Thus, while in vitro receptor binding affinities, efficacies, and average concentrations in tissue or plasma are useful, they are not likely to predict DMT concentrations in the vesicles or at synaptic or intracellular receptors. Under these conditions, notions of receptor selectivity are moot, and it seems probable that most of the receptors identified as targets for DMT (see above) participate in producing its psychedelic effects. DMT produces the head-twitch response (HTR), a behavioral proxy of psychedelic-like effects, in rodents. However, its effects in the HTR paradigm in mice that are highly strain-dependent, including producing an HTR comparable to other psychedelics, producing an HTR that is much weaker than that of other psychedelics, or producing no HTR at all. These conflicting results may be due to rapid metabolism of DMT and/or other peculiarities of DMT in different species. Besides the HTR, DMT also substitutes for LSD and DOM in rodent drug discrimination tests. DMT has been found to increase oxytocin levels in humans. It is thought that the rate at which DMT enters the brain, and hence its route of administration, may influence its effects, with more rapid routes like intravenous administration and inhalation potentiating serotonin 5-HT2A receptor activation and consequent hallucinogenic effects. As an example, a bolus intravenous injection of 15 mg DMT produces stronger peak effects than a continuous infusion of 1 mg/minute given over 1.5 hours in spite of the latter achieving higher peak DMT levels.
Narrated by Piers Gibbon, produced by Simon Nasht, directed by Chris Durlacher, made by Pilot Productions, with WGBH Nova and Rai 3 (Rai Tre) of Italy, and AVRO (AVROTROS since 2014) of the Netherlands 26 April Sweden, Sex and the Disappearing Doctors, about compulsory sterilisation in Sweden, after a law was passed in 1934; until 1975, the Swedish government had compulsory sterilised 60,000 citizens; the forty-year programme began as a eugenics programme to breed a Nordic race; historian Gunnar Broberg; environment minister Anna Lindh; writer Jan Myrdal; individuals who were unlikely to financially contribute to the Swedish state, not intelligent, or who had been labelled as anti-social, were most likely to be forcibly sterilised; anti-social youths were given the choice between being sterilised or prison; 90% of people sterilised were women, and many were single mothers of limited means; oral contraceptives made the sterilisation programme redundant; the State Institute for Racial Biology in Uppsala, and geneticist Ulf Pettersson; the documentary was conducted in a hard-hitting confrontational Panorama-style.
=== Shark repellent === P. marmoratas and P. pavoninus release pardaxin when threatened by sharks. Pardaxin targets the gills and pharyngeal cavity of the sharks. It results in severe struggling, mouth paralysis, and temporary increase of urea leakage in the gills. This distress is caused by the attack of the cellular membrane of the gills, which causes a large influx of salt ions. Research into creating a commercial shark repellent using pardaxin was discontinued because it dilutes in the water too quickly. It is only effective if sprayed almost directly into a shark's mouth.
Aside from adult transgender people, CPA has also been used as a puberty blocker and hence as an antiandrogen and antiestrogen to suppress puberty in transgender adolescents, although GnRH modulators are primarily used and more effective for this purpose.
Sources: en.wikipedia.org
The chief advantage sirolimus has over calcineurin inhibitors is its low toxicity toward kidneys. Transplant patients maintained on calcineurin inhibitors long-term tend to develop impaired kidney function or even kidney failure; this can be avoided by using sirolimus instead. It is particularly advantageous in patients with kidney transplants for hemolytic–uremic syndrome, as this disease is likely to recur in the transplanted kidney if a calcineurin-inhibitor is used. However, on 7 October 2008, the FDA approved safety labeling revisions for sirolimus to warn of the risk for decreased renal function associated with its use. In 2009, the FDA notified healthcare professionals that a clinical trial conducted by Wyeth showed an increased mortality in stable liver transplant patients after switching from a calcineurin inhibitor-based immunosuppressive regimen to sirolimus. A 2019 cohort study of nearly 10,000 lung transplant recipients in the US demonstrated significantly improved long-term survival using sirolimus + tacrolimus instead of mycophenolate mofetil + tacrolimus for immunosuppressive therapy starting at one year after transplant. Sirolimus can also be used either alone or in conjunction with a calcineurin inhibitor (such as tacrolimus) or mycophenolate mofetil, or both, to provide steroid-free immunosuppression regimens.
A vocal lobby of anti-trans actors as part of the anti-gender movement attempt to spread misinformation regarding transgender health care, attempting to influence governments and the public and to deny legal recognition of transgender and gender diverse people and access to gender-affirming health care. The United Nations Independent Expert on sexual orientation and gender identity published the IESOGI Reports on Gender: The Law of Inclusion & Practices of Exclusion in 2021 that was presented at the 47th UN Human Rights Council and 76th UN General Assembly which highlighted laws violating the Universal Declaration of Human Rights and called out a series of alleged threats perpetuated by anti-trans actors in the spread of misinformation around transgender people's rights and related health care. This misinformation has resulted in some countries passing laws violating people's basic human rights such as denying legal gender recognition and restrictions on access to gender-affirming treatments, particularly for transgender youth who are being restricted from access to hormone treatments such as puberty blockers.
The efficacy of quinacrine was assessed in a rigorous clinical trial in the UK and the results were published in Lancet Neurology, and concluded that quinacrine had no measurable effect on the clinical course of CJD. Astemizole, a medication approved for human use, has been found to have anti-prion activity and may lead to a treatment for Creutzfeldt–Jakob disease. A monoclonal antibody (code name PRN100) targeting the prion protein (PrP) was given to six people with Creutzfeldt–Jakob disease in an early-stage clinical trial conducted from 2018 to 2022. The treatment appeared to be well-tolerated and was able to access the brain, where it might have helped to clear PrPC. While the treated patients still showed progressive neurological decline, and while none of them survived longer than expected from the normal course of the disease, the scientists at University College London who conducted the study see these early-stage results as encouraging and suggest conducting a larger study, ideally at the earliest possible intervention.
This work led to the development of an ion mobility-quadrupole-CID-TOFMS instrument by Micromass in the UK and ultimately led Micromass / Waters corporation to develop of the world's first commercial ion mobility-mass spectrometer instrument in 2006. The Synapt, as it is called, incorporates a pre ion mobility quadrupole allowing precursor ion selection prior to IMS separation further enhancing the flexibility of the ion mobility-mass spectrometry combinations. In 2013, Agilent Technologies released the first commercial drift tube ion mobility-mass spectrometer named 6560 with an 80 cm drift tube. Ion funnels are used to improve the ion transmission efficiency. The design thus greatly improved the sensitivity of ion mobility and allowed commercialization. A variation of IMS-MS is differential ion mobility spectrometry-mass spectrometry (DIMS-MS), in which gas phase ions are separated based on their ion mobility in varying strengths of electric fields. This analytical method is currently being advanced by Gary Glish and the Glish Group.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.